---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-024036"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:17:22.695633+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Q2 2025 net loss $4.1M; CyPath Lung revenue up 62% H1

## Summary
- Total revenue $1.3M in Q2 2025 vs $2.4M in Q2 2024, reflecting discontinuation of unprofitable pathology services.
- CyPath Lung testing revenue grew 62% YTD to $323K; monthly tests set records in June and July.
- Net loss $4.1M ($0.17/share) vs $2.1M ($0.19/share) in Q2 2024, increase driven by non-cash warrant remeasurement and offering costs.
- Cash $0.8M at June 30, 2025; completed $3.25M public offering in May 2025 to bolster working capital.
- Appointed Dr. Gordon Downie as CMO; expanded IP portfolio with patents in US, China, Canada, Australia.

## SEC filing metadata
- accession: 0001641172-25-024036
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/0001641172-25-024036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-024036
- JSON: https://secwatch.observer/filing/0001641172-25-024036.json
- Plain text: https://secwatch.observer/filing/0001641172-25-024036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.